| Literature DB >> 28182564 |
Claus F Vogelmeier1,2, Gerard J Criner3,2, Fernando J Martinez4,2, Antonio Anzueto5, Peter J Barnes6, Jean Bourbeau7, Bartolome R Celli8, Rongchang Chen9, Marc Decramer10, Leonardo M Fabbri11, Peter Frith12, David M G Halpin13, M Victorina López Varela14, Masaharu Nishimura15, Nicolas Roche16, Roberto Rodriguez-Roisin17, Don D Sin18, Dave Singh19, Robert Stockley20, Jørgen Vestbo19, Jadwiga A Wedzicha6, Alvar Agusti21.
Abstract
This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28182564 DOI: 10.1183/13993003.00214-2017
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671